Nov 04, 2024
CrossBridge Bio Secures $10M Investment to Revolutionize Cancer Treatment with Dual-Payload ADCs. (Source)
BigHat Biosciences teams up with Synaffix to develop next-generation antibody-drug conjugates (ADCs) using cutting-edge platform technology and drug discovery techniques. Antibody-drug conjuugate, platform tech, drug discovery (Source)
Oct 24, 2024
ABL Bio and IntoCell Join Forces to Develop Innovative Antibody-Drug Conjugates for Cancer Treatment. (Source)
ZL-1310, Zai Labs‘ investigational DLL3-targeting ADC, shows positive Phase 1a/b data in extensive-stage small-cell lung cancer, boosting company shares. (Source)
Oct 21, 2024
Perseus Proteomics and UBE sign a research deal for Antibody-Drug Conjugates (ADC) development. Antibody-drug conjugate, research & development, drug discovery (Source)
Oct 18, 2024
LaNova Medicines raised $42 million in Series C1 funding. Antibody-drug conjugate, cancer, monoclonal antibody, drug discovery platform (Source)
Gilead Sciences announced plans to voluntarily withdraw U.S. approval for Trodelvy®, a drug used to treat advanced urothelial cancer in patients who’ve previously received platinum-based chemotherapy and PD-1 or PD-L1 inhibitors. (Source)
Oct 14, 2024
Enhertu, a promising antibody-drug conjugate developed by Novartis and Daiichi Sankyo, has received regulatory approval for lung cancer treatment in China. (Source)
About “Antibody-drug conjugate”
Antibody-drug conjugates (ADCs) are a type of therapeutic agent that combines the targeting specificity of monoclonal antibodies with the cytotoxic potency of potent small molecules. They are designed to deliver potent drugs directly to cancer cells, minimizing damage to healthy tissues.
Here’s how ADCs work:
- Monoclonal antibody: The antibody component is highly specific to a target molecule, usually a protein overexpressed on cancer cells. This ensures that the ADC only binds to and delivers the drug to the intended target.
- Linker: The linker connects the antibody to the drug. This linker is crucial for releasing the drug inside the cancer cell.
- Drug: The drug component is a potent cytotoxic agent that can kill cancer cells. It is designed to have minimal toxicity to healthy cells.
When an ADC binds to the target molecule on the surface of a cancer cell, it is internalized into the cell. The acidic environment within the cell triggers the release of the drug from the linker. The released drug can then exert its cytotoxic effect, leading to cell death.
ADCs have shown promise in treating various types of cancer, including breast cancer, hematological malignancies, and solid tumors. They offer a targeted approach to cancer therapy, potentially improving treatment outcomes while reducing side effects.
